Objective
to assess the clinical outcomes of a bioadaptor implant compared to drug-eluting stents for treatment of ischaemic heart disease. Bioadaptor: restores haemodynamic modulation of the coronary artery (vasomotion and adaptive remodelling)
Study
single-blind, registry-based, randomised noninferiority trial (margin 4.2%)
Population
patients with chronic or acute coronary syndrome. Excluded left -main CAD, chronic total occlusion and severe calcification
Endpoints
target lesion failure as cardiovascular death, MI and ischaemia-driven target lesion revascularisation at 1 year
Conclusion
the bioadaptor implant was noninferior to contemporary DES during 1-year follow-up after treatment for chronic or acute coronary syndromes
Erlinge et al. Lancet 2024;404:1750-1759
